Orlando Health Ventures

Orlando Health Ventures is the corporate venture capital arm of Orlando Health, one of Central Florida's largest nonprofit integrated healthcare systems, established in 2018 and based in Orlando, Florida. The unit sits inside the Orlando Health Strategic Innovations group alongside The Foundry, Orlando Health's internal innovation and rapid-prototyping engine, giving portfolio companies direct access to clinicians, operating executives, and service-line leaders for evaluation, piloting, and commercial validation. The fund targets early-stage companies whose technologies have the potential to transform care delivery, clinical workflows, and patient outcomes. Orlando Health Ventures has made approximately nine disclosed investments concentrated in medical devices and digital health. Portfolio companies include 410 Medical (rapid IV medication delivery, with a Series B-II round in March 2025 as the firm's most recent disclosed investment), Biostable Science and Engineering (Austin-based heart-valve repair device as an alternative to replacement, with roughly $1.25 million deployed), and Vesalio (neurovascular thrombectomy devices whose NeVa VS system launched at Wellstar Health System in Atlanta). The fund participates in seed through Series B rounds alongside peer health-system corporate venture arms such as UPMC Enterprises. What distinguishes Orlando Health Ventures is its combination of clinician-led diligence and operational pilot capability. Portfolio companies can run structured pilots within the Orlando Health system, gaining real-world evidence and commercial traction while the fund's investment committee evaluates growth trajectory and return potential. The result is a capital partner that brings both funding and a credible path to enterprise healthcare customers.